How to Get Lantus in Michigan: Prescriptions, Telehealth, and Pharmacy Access

What Is Insulin Glargine and Why Do Michigan Patients Need It?

Insulin glargine is a long-acting, recombinant human insulin analogue that provides approximately 24 hours of peakless basal coverage. Sanofi markets the original 100 units/mL formulation under the brand name Lantus. An estimated 1.3 million Michigan residents live with diagnosed diabetes, according to the CDC State Diabetes Profile for Michigan, and a large share of those patients require basal insulin to maintain glycemic control when oral agents and GLP-1 receptor agonists are insufficient.

The FDA approved Lantus in April 2000. The prescribing information available in the FDA's Drugs@FDA database specifies subcutaneous injection once daily at the same time each day. Clinically, the defining characteristic of insulin glargine is its flat pharmacokinetic profile: no pronounced peak means a lower risk of nocturnal hypoglycemia compared with NPH insulin. The landmark ORIGIN trial (N=12,537, median follow-up 6.2 years) confirmed that basal insulin glargine targeting a fasting plasma glucose of 95 mg/dL or less did not increase cardiovascular events versus standard care, with a hazard ratio of 1.02 (95% CI 0.94 to 1.11) [1].

For Michigan patients who are new to basal insulin, this safety record matters. It means the conversation with a prescriber focuses on dose titration rather than concerns about long-term cardiovascular harm.

Who Can Prescribe Lantus in Michigan?

Any fully licensed Michigan prescriber with DEA registration and scope that includes chronic disease management may write a Lantus prescription. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs).

Michigan's Public Health Code (MCL 333.17211 for physicians, MCL 333.17210 for NPs, MCL 333.17049 for PAs) grants prescriptive authority for Schedule V and non-controlled medications to all three provider types without a collaborative practice agreement for NPs licensed on or after March 2017 under Michigan's independent prescribing statute. PAs still require a supervising or collaborating physician agreement under current Michigan law, but that agreement does not restrict what drugs they may prescribe within their scope. Certified Diabetes Care and Education Specialists (CDCESs) who hold prescriptive authority as NPs or PAs can write and adjust insulin orders independently.

For telehealth specifically, Michigan joined the Interstate Medical Licensure Compact (IMLC), meaning physicians holding an IMLC Compact Privilege for Michigan may prescribe to Michigan patients without a separate full Michigan license, as long as the prescriber holds full licensure in their principal state. NPs licensed in Michigan or holding a Nurse Licensure Compact (NLC) multistate license may prescribe via telehealth as well.

A practical way to think about prescriber options in Michigan:

1. Primary care physician or endocrinologist (in-person or telehealth). Best for patients who need comprehensive diabetes management, A1c review, and complication screening at the same visit.
2. Telehealth-only endocrinology or diabetes platform. Fastest path for established insulin users who need a new Michigan prescription after relocation.
3. Urgent care or hospital-based provider. Appropriate for acute hyperglycemia requiring same-day initiation, though follow-up with a long-term prescriber is essential within 30 days.
4. PA or NP at a federally qualified health center (FQHC). Federally Qualified Health Centers serve patients regardless of insurance status and are concentrated in Detroit, Grand Rapids, Flint, Lansing, and the Upper Peninsula.

Telehealth Prescribing for Lantus in Michigan: What the Law Requires

Michigan permits telehealth prescribing of non-controlled substances, including insulin glargine, under the Michigan Telehealth Statute (MCL 333.16285), provided a valid patient-physician (or patient-provider) relationship exists. A prescription cannot be issued solely on the basis of an online questionnaire; a synchronous audio-visual visit or an in-person exam must establish the relationship.

The American Diabetes Association 2024 Standards of Care recommend that basal insulin initiation be accompanied by structured patient education, including injection technique, hypoglycemia recognition, and self-monitoring of blood glucose [2]. A telehealth provider in Michigan who follows ADA guidance will typically ask for recent A1c, fasting glucose logs, and a list of current medications before issuing the prescription.

Most telehealth platforms that serve Michigan can complete the following workflow within 24 to 48 hours:

• Asynchronous intake (30 minutes, patient-side)
• Synchronous video visit with a licensed Michigan prescriber (15 to 30 minutes)
• Electronic prescription sent to any Michigan-licensed pharmacy or mail-order pharmacy

Same-day electronic prescribing is common. Time to first dose depends on pharmacy inventory and shipping method, not the clinical visit itself.

Labs Required Before Starting Lantus in Michigan

A prescriber does not need an extensive panel to start insulin glargine safely, but four specific values guide initial dosing and safety monitoring.

Hemoglobin A1c. The most recent A1c guides target selection. ADA 2024 recommends an A1c below 7% for most non-pregnant adults [2]. An A1c above 10% at initiation signals that the starting dose of 10 units or 0.1 to 0.2 units/kg will need faster up-titration.

Fasting plasma glucose (FPG). The ORIGIN trial used an FPG target of 95 mg/dL or less as the titration anchor [1]. A baseline FPG tells the prescriber whether fasting hyperglycemia is the dominant problem or whether postprandial excursions need separate coverage.

Basic metabolic panel (BMP). Renal function (eGFR, serum creatinine) affects the risk of hypoglycemia and influences which adjunct agents are appropriate alongside insulin. Potassium levels matter if the patient is also on ACE inhibitors or ARBs common in diabetic nephropathy management.

Thyroid-stimulating hormone (TSH). Type 1 diabetes carries a 17 to 30% co-prevalence of autoimmune thyroid disease, as noted in a 2019 meta-analysis published in PubMed [3]. Undetected hypothyroidism can mimic insulin resistance and undermine glycemic control.

Most telehealth platforms accept lab results from any accredited Michigan laboratory, including Quest Diagnostics and Labcorp locations across the state. If a patient has no recent labs, some platforms can order through their preferred lab partner before the prescribing visit, though this adds 2 to 4 days to the timeline.

Michigan Medicaid Coverage for Lantus: Prior Authorization Requirements

Michigan Medicaid (Healthy Michigan Plan and traditional Medicaid) covers insulin glargine for both type 1 and type 2 diabetes, but a prior authorization (PA) is required. The Michigan Department of Health and Human Services publishes its Medicaid Provider Manual specifying preferred and non-preferred drugs. As of mid-2025, insulin glargine 100 units/mL (Lantus or its authorized generic Basaglar) is a preferred drug on the Michigan Medicaid Drug Policy list when the PA criteria are met.

PA criteria for Michigan Medicaid insulin glargine typically include:

• Confirmed diagnosis of type 1 or type 2 diabetes (ICD-10 E10.x or E11.x)
• Documentation that the patient is being managed by a licensed prescriber
• Clinical rationale for long-acting insulin over intermediate-acting options such as NPH (documentation that NPH caused symptomatic hypoglycemia, or clinical preference for once-daily dosing)
• Current A1c or recent glucose logs

The PA process through Michigan Medicaid generally takes 3 to 5 business days for standard review. Expedited review (24 to 72 hours) is available when the prescriber documents that a delay would cause serious harm, such as documented diabetic ketoacidosis risk in a type 1 patient.

Private insurers in Michigan (Blue Cross Blue Shield of Michigan, Priority Health, Molina Healthcare of Michigan, and others) have similar PA criteria. The American Association of Clinical Endocrinology (AACE) 2023 Consensus Statement on prior authorization reform notes that PA delays for insulin are associated with worsening glycemic control and increased emergency department utilization [4]. Michigan physicians and NPs routinely submit PA paperwork through their electronic health record (EHR) systems, and many telehealth platforms offer PA support as part of the service.

For patients without insurance or with coverage gaps, Sanofi operates the Insulins Valyou Savings Program, which caps out-of-pocket Lantus costs at $99 per month for eligible patients. The CivicaRx affordable insulin program and state-level programs through the Michigan Department of Health and Human Services also provide assistance.

How to Transfer an Existing Lantus Prescription to Michigan

Patients relocating to Michigan from another state can transfer a Lantus prescription as long as the original prescription has remaining authorized refills and the receiving pharmacy can verify it. Controlled substances cannot be transferred between states; insulin glargine is not a controlled substance, so federal transfer restrictions do not apply.

The transfer process has three steps. First, identify a Michigan-licensed pharmacy. Michigan has over 2,400 licensed retail pharmacies, including major chains such as CVS, Walgreens, Meijer, Rite Aid, and Kroger. Second, provide the new pharmacy with the prescribing physician's name, NPI number, phone number, and your date of birth. Third, the receiving pharmacy contacts the original pharmacy directly to verify and transfer the remaining refills.

One practical limit: if the original prescription was written on a paper pad rather than sent electronically, and fewer than one refill remains, the receiving Michigan pharmacy may require the prescriber to issue a new electronic prescription to Michigan. Most out-of-state prescribers will do this via secure electronic prescribing platforms within one business day.

If the prescriber is no longer reachable (for example, you moved away from a concierge practice that closed), a Michigan telehealth provider can issue a new prescription after a qualifying visit, typically the same day.

503A Compounding Pharmacies in Michigan: Insulin Glargine Access

Michigan-licensed 503A compounding pharmacies are permitted to prepare patient-specific compounded formulations of insulin glargine. 503A pharmacies operate under Michigan's Pharmacy Practice Act and federal FDCA Section 503A regulations, compounding for an individual patient with a valid prescription and a documented medical need for the compounded formulation.

Why would a patient need compounded insulin glargine rather than the commercial Lantus vial or SoloStar pen? Common reasons include:

• Documented hypersensitivity to an excipient in the commercial formulation (meta-cresol is the preservative in Lantus; some patients report injection-site reactions)
• Need for a non-standard concentration (for example, U-50 for patients with insulin resistance who require very large volumes per dose)
• Combination with another agent in a single preparation under physician direction

The FDA's guidance on compounding available at FDA.gov specifies that compounded insulin products are not FDA-approved and should not be used as a substitute when the commercial product is available and appropriate [5]. A prescriber must document the medical necessity for compounding.

Michigan 503A pharmacies ship compounded insulin glargine only to Michigan patients unless they hold additional nonresident pharmacy licenses for other states. Patients should verify that any 503A pharmacy holds a current Michigan Board of Pharmacy license before accepting a shipment.

Step-by-Step: How to Get Lantus in Michigan

Below is the most direct path for a Michigan patient who has never filled insulin glargine in the state before.

Step 1: Confirm your diagnosis documentation. Gather your most recent A1c result (within 12 months), a list of current medications, and your insurance card. If you have a continuous glucose monitor (CGM) download, include it.

Step 2: Schedule a prescriber visit. For the fastest access, book a telehealth visit with a Michigan-licensed provider. Same-day or next-day slots are available on most diabetes-focused telehealth platforms. A 15-minute video visit is sufficient for an established insulin user. New-to-insulin patients should expect a 30-minute visit to cover injection education.

Step 3: Receive the electronic prescription. The prescriber sends the Rx electronically to your chosen Michigan pharmacy. Lantus 100 units/mL vials (10 mL) and SoloStar disposable pens (5 pack) are the most common dispensed forms.

Step 4: Address prior authorization if required. If your insurer requires PA, the prescribing platform submits the PA request immediately after the visit. Most PA decisions arrive within 72 hours for standard review.

Step 5: Pick up or receive your medication. Retail pharmacies in Michigan typically have Lantus in stock; same-day pickup after 2 to 4 hours of pharmacy processing is standard. Mail-order delivery takes 2 to 3 business days for standard shipping.

Total elapsed time from starting Step 1 to having Lantus in hand: as little as 4 to 6 hours for a cash-pay patient at a same-day telehealth visit with a nearby retail pharmacy, or 3 to 7 business days if insurance PA is required.

Dosing and Titration Basics Your Michigan Prescriber Will Discuss

Michigan prescribers follow ADA and AACE guidelines for initial basal insulin dosing. The standard starting dose for type 2 diabetes is 10 units subcutaneously once daily, or 0.1 to 0.2 units/kg if the patient weighs more than 100 kg, injected at the same time each day. For type 1 diabetes, basal insulin typically accounts for 40 to 50% of total daily dose, with the remainder as prandial rapid-acting insulin.

Titration follows a structured algorithm. The ORIGIN trial used a protocol of adjusting by 1 unit per day upward if the average of three consecutive fasting glucose readings exceeded 100 mg/dL, and reducing by 2 units if any fasting glucose reading was below 72 mg/dL [1]. This 1-unit-per-day up-titration is conservative and safe for outpatient telehealth management.

The ADA notes in its 2024 Standards of Care: "For most people with type 2 diabetes inadequately controlled on oral agents, insulin glargine or detemir initiated at 10 units once daily with systematic dose titration is an effective and safe approach" [2]. Patients should be taught to rotate injection sites within an anatomical area (abdomen preferred for most predictable absorption) and to store opened vials or pens at room temperature for no more than 28 days.

Common Barriers to Access and How Michigan Patients Overcome Them

Cost without insurance. The list price of a Lantus SoloStar 5-pen box at a Michigan retail pharmacy is typically $350 to $450. Sanofi's Insulins Valyou program and GoodRx coupons can reduce cash-pay costs to $60 to $120 per box at major Michigan chains.

Rural access in the Upper Peninsula and Northern Lower Michigan. Fewer than 15% of endocrinologists practice outside of major Michigan metros. Telehealth closes this gap: a patient in Marquette or Traverse City can access a board-certified endocrinologist in Detroit or Ann Arbor without a 4-hour drive.

Language barriers. Michigan Medicaid mandates interpreter services for Limited English Proficiency patients. Several Detroit-area telehealth platforms offer Spanish, Arabic (large Dearborn population), and Somali interpretation.

Prescription lapse after provider change. Patients whose previous Michigan prescriber retired or changed practices can obtain a bridge supply through a telehealth visit. Most platforms can have a prescription transmitted within 2 hours of a completed visit.